Guozhi Tang

720 Cailun Road
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.

Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.

Journal: Journal of medicinal chemistry

Published: October 06, 2021

EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.

EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.

Journal: Journal of medicinal chemistry

Published: June 26, 2020

A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles.

A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles.

Journal: Journal of medicinal chemistry

Published: November 06, 2019

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.

Journal: Journal of medicinal chemistry

Published: March 25, 2017

Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms.

Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms.

Journal: Scientific reports

Published: October 06, 2016

Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.

Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 27, 2016

Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.

Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.

Journal: ACS medicinal chemistry letters

Published: May 18, 2016

Identification of New ATG4B Inhibitors Based on a Novel High-Throughput Screening Platform.

Identification of New ATG4B Inhibitors Based on a Novel High-Throughput Screening Platform.

Journal: SLAS discovery : advancing life sciences R & D

Published: March 20, 2016

Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.

Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.

Journal: Journal of medicinal chemistry

Published: March 04, 2015

Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.

Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.

Journal: Journal of medicinal chemistry

Published: September 20, 2014

Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.

Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.

Journal: Journal of medicinal chemistry

Published: October 16, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026